Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease.
Marta Di PasqualeStefano AlibertiMarco ManteroAndrea GramegnaFrancesco BlasiPublished in: Expert opinion on pharmacotherapy (2020)
As acute exacerbations are a main common and detrimental event in patients with COPD and bronchiectasis, effective antimicrobial therapies and regimens should be optimized. The development of new molecules or combination regimens is vital to patients with severe and/or difficult-to-treat infections. Moreover, chronic infection control is mandatory in these patients to their improve quality of life, respiratory function and prognosis as well as for reducing health care costs.
Keyphrases
- cystic fibrosis
- chronic obstructive pulmonary disease
- lung function
- pseudomonas aeruginosa
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- drug induced
- liver failure
- staphylococcus aureus
- peritoneal dialysis
- early onset
- hepatitis b virus
- respiratory failure
- patient reported
- acute respiratory distress syndrome
- aortic dissection